[Effect and tolerance of Biarison (proquazone) in rheumatoid arthritis (author's transl)].
Biarison was tested in 24 patients mainly with classical rheumatoid arthritis for its efficacy and tolerance. There was a distinct improvement in the course of the 4 weeks' therapy with a mean dosage of 900 mg/day (it was in the meantime raised to a maximum of 1500 mg/day in isolated cases) especially in the pain, stiffness and functional capacity. Biarison caused few gastrointestinal side effects: the tolerance may be said to be good on the whole.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002908:Chronic Disease; D006801:Humans; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011799:Quinazolines
Wirkung und Verträglichkeit von Biarison (Proquazon) bei chronischer Polyarthritis.